Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (PYXS) is a clinical-stage biopharmaceutical company pioneering antibody-drug conjugates (ADCs) targeting components of the tumor microenvironment to address challenging cancers. This page provides investors and researchers with a comprehensive repository of official announcements, clinical trial updates, and strategic developments.
Access timely updates on PYX-201 progress, partnership agreements, and regulatory milestones. Our curated collection includes earnings reports, preclinical data disclosures, and management commentary – all essential for evaluating the company’s position in oncology innovation.
Key content categories include ADC platform advancements, clinical trial phase transitions, and scientific collaborations. Users will find verified information on therapeutic mechanisms targeting extracellular matrix proteins like EDB+FN, a focus area distinguishing Pyxis in immuno-oncology.
Bookmark this page for streamlined access to material events affecting Pyxis Oncology’s trajectory. Check regularly for new developments in their pipeline programs and evidence-based analysis of therapeutic candidates.
Pyxis Oncology (Nasdaq: PYXS) reported full-year 2022 financial results and updates on its clinical trials. The company has initiated two Phase 1 trials for its candidates PYX-201 and PYX-106, with preliminary data expected by early 2024. As of year-end 2022, Pyxis maintained a strong balance sheet with $180.7 million in cash and no debt, funding operations into 1H 2025. Research and development expenses rose to $86.1 million, while general and administrative costs increased to $37.4 million, leading to a net loss of $120.7 million for 2022, equating to ($3.65) per share. The company also received FDA clearance for both candidates' INDs.
Pyxis Oncology (Nasdaq: PYXS) has achieved a major milestone by initiating dosing in a Phase 1 clinical trial of PYX-201, a novel antibody-drug conjugate targeting extradomain-B of fibronectin, which is overexpressed in various solid tumors. The trial aims to evaluate the safety and efficacy of PYX-201 with preliminary data expected in early 2024. The company emphasizes its innovative approach using three mechanisms of action to potentially improve treatment for patients with solid tumors. The trial is open to patients with relapsed or refractory cancers, paving the way for future therapeutic advancements.
Pyxis Oncology (Nasdaq: PYXS) is set to host investor meetings on February 15, 2023, during the SVB Securities Global Biopharma Conference, which will occur virtually. Key executives attending include Lara Sullivan, M.D. (President & CEO), Pamela Connealy (CFO), Jay Feingold, M.D., Ph.D. (CMO), and Jan Pinkas, Ph.D. (CSO). Institutional investors interested in participating can contact their SVB Securities representative or Jennifer Davis Ruff, VP of Investor Relations.
Pyxis Oncology focuses on developing next-generation therapeutics aimed at difficult-to-treat cancers, utilizing strategies such as antibody-drug conjugates and immuno-oncology programs.
On December 23, 2022, Pyxis Oncology (Nasdaq: PYXS) announced that its Compensation Committee granted a total of 52,560 restricted stock units and 65,701 stock options to five new employees under the 2022 Inducement Plan. These awards are part of the company’s strategy to attract talent as it develops next-generation therapeutics for tough cancers. The stock options, with an exercise price of $1.28, vest over four years, with a quarter vesting after the first year. This move aligns with Nasdaq regulations.
Pyxis Oncology has announced that the FDA granted IND clearances for its two product candidates: PYX-201, an antibody-drug conjugate, and PYX-106, an immunotherapy. Both candidates will enter Phase 1 clinical trials to assess their safety and anti-tumor activities against select solid tumors, such as breast and lung cancers. This marks a significant milestone for the company, as it extends its cash runway into 2025, enabling further clinical development of therapies aimed at addressing unmet medical needs in oncology.
Pyxis Oncology expands its licensing agreement with Pfizer, gaining exclusive rights to its antibody-drug conjugate (ADC) technology platform. This includes the ability to sublicense components to third parties, with a successful initial agreement already in place. The company is on track for IND applications for PYX-106 and PYX-201 by year-end. Financially, as of September 30, 2022, Pyxis has $200 million in cash, supporting operations into 2024. However, Q3 2022 reported a net loss of $27.7 million, reflecting rising R&D and administrative expenses.
On September 30, 2022, Pyxis Oncology (Nasdaq: PYXS) announced the grant of restricted stock units for 213,030 shares and stock options for 266,290 shares to 17 newly hired employees under its 2022 Inducement Plan. These awards are part of a strategy to attract talent and are in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term with an exercise price of $1.97. The vesting schedule includes 25% vesting on the first anniversary, with the balance vesting monthly over the following three years, contingent on continued employment.
Pyxis Oncology (PYXS) reported a Q2 net loss of $25.6 million, or $(0.79) per share, compared to $(5.54) per share a year prior. As of August 15, 2022, the company had a cash balance of $207 million, providing runway through H2 2024. Key highlights include a focus on advancing two lead programs: PYX-201, an ADC, and PYX-106, an mAb, with IND filings expected in 2022. PYXS has paused two programs (PYX-203 and PYX-102) and ceased development of PYX-202. The company appointed Dr. Rachel Humphrey to its Board, enhancing its expertise in oncology drug development.
On July 1, 2022, Pyxis Oncology (Nasdaq: PYXS) announced the granting of restricted stock units totaling 61,360 shares and stock options for 76,701 shares to four new employees. This grant falls under the 2022 Inducement Plan and complies with Nasdaq rules. The stock options feature an exercise price of $2.44, corresponding to the closing share price on the grant date. Vesting occurs over four years, with 25% vesting after one year, and the remaining shares vest monthly thereafter. This initiative aims to bolster the company’s talent and support its development of therapeutics for hard-to-treat cancers.
Pyxis Oncology, Inc. (Nasdaq: PYXS), focused on next-generation cancer therapeutics, will present at the H.C. Wainwright Preclinical Cancer Drug Discovery conference. The presentation, featuring Lara Sullivan, M.D., and Jay Feingold, M.D., Ph.D., will be available on-demand starting at 9:00 a.m. ET on June 29, 2022. A webcast will also be accessible on the Pyxis Oncology investor relations site and will be archived for 90 days.
Founded in 2019, Pyxis develops antibody drug conjugates and monoclonal antibodies to tackle challenging cancers.
FAQ
What is the current stock price of Pyxis Oncology (PYXS)?
What is the market cap of Pyxis Oncology (PYXS)?
